Juvenile Idiopathic Arthritis Deep Research Fallback

Provider Attempts

No deep-research provider was invoked for this root-level entry. There is no existing subtype dismech file for any ILAR category, so this record was curated directly from the verified literature already cached in references_cache/ that addresses JIA at the umbrella level.

Integrated Literature Synthesis

Juvenile idiopathic arthritis (JIA, MONDO:0011429) is an umbrella term for the chronic arthritides of childhood beginning before 16 years of age and persisting for at least six weeks, after exclusion of infective, traumatic, malignant, and other defined causes. The International League of Associations for Rheumatology (ILAR) criteria stratify JIA into seven clinically distinct categories — oligoarticular, polyarticular rheumatoid-factor-negative, polyarticular rheumatoid- factor-positive, systemic, psoriatic, enthesitis-related, and undifferentiated. PMID:29848426 ("Spectrum of Joint Deformities in Children with Juvenile Idiopathic Arthritis") cites the ILAR criteria as the operational basis for cohort enrolment in JIA studies.

Mechanistic axis: autoimmune vs autoinflammatory. PMID:29037901 frames the heterogeneity directly: "Juvenile Idiopathic Arthritis (JIA) is characterized with a variable pattern of articular involvement and systemic symptoms and, thus, it has been classified in several subtypes." Oligoarticular, polyarticular and RF-positive forms have an adaptive-autoimmune flavour with HLA-class-II linkage (HLA-DRB108, 01, *04 alleles depending on subset); systemic JIA is dominated by innate-immune activation with prominent IL-1 and IL-6 signalling.

PMID:38756937 and PMID:39317417 establish the Still's disease continuum between systemic JIA and adult-onset Still's disease, and define the modern therapeutic strategy: "The optimal therapeutic strategy relies on early use of interleukin (IL-1 or IL-6 inhibitors associated to short duration glucocorticoid (GC)." This is captured here as a separate Systemic Autoinflammation (sJIA) pathophysiology node.

Synovial mechanism atomic decomposition. Per the PR review feedback, the original single Synovial Inflammation node has been decomposed into three atomic nodes connected via downstream edges:

1. Synovial Leukocyte Infiltration — T-cell and macrophage recruitment to the synovial membrane (UBERON:0002018, CL:0000235, GO:0006955 ABNORMAL).
2. Synovial Hyperplasia — synoviocyte proliferation (CL:0000214).
3. Cytokine-Mediated Articular Damage — TNF / IL-1 / IL-6 -driven cartilage and bone destruction (GO:0001816 INCREASED).

Chronic anterior uveitis is the major extra-articular complication of oligoarticular JIA and a leading cause of visual morbidity if unscreened. It is now captured as a subtype-qualified phenotype (HP:0012122 Anterior uveitis, temporality: CHRONIC, subtype: Oligoarticular). Acute symptomatic uveitis also occurs in enthesitis-related JIA but is not the same phenotype.

Treatment ladder. NSAIDs (MAXO:0000221), intra-articular and short-course systemic glucocorticoids, methotrexate as the conventional synthetic DMARD of first choice for polyarticular / extended- oligoarticular JIA, and biologic DMARDs targeting TNF (etanercept, adalimumab), IL-1 (anakinra, canakinumab), and IL-6 (tocilizumab), with IL-1 / IL-6 inhibitors moving earlier in the treatment paradigm for systemic JIA per the EULAR/PReS recommendations.

Out of scope for the root entry

• Subtype-specific molecular details and complication profiles (macrophage activation syndrome in sJIA, the full spectrum of drug-specific dosing and adverse effects, etc.). Scoped as follow-up dismech entries per ILAR category.
• Genetic-association detail beyond HLA-DRB1 — additional susceptibility loci (PTPN22, IL2RA, IL6, IL10) and the genetic overlap with adult rheumatoid arthritis are scoped as follow-up.
• The Still's-disease end of the continuum in adults (adult-onset Still's disease) — should be its own dismech entry rather than duplicated here.